<DOC>
	<DOCNO>NCT00224133</DOCNO>
	<brief_summary>A new drug benign prostatic hyperplasia use 9 month determine long-term safety .</brief_summary>
	<brief_title>The Evaluation Safety New Drug Benign Prostatic Hyperplasia Used 9 Months</brief_title>
	<detailed_description>This multi-center , open-label 40 week investigation 1,200 men sign symptom benign prostatic hyperplasia . The following procedure utilized : physical exam , electrocardiogram , clinical laboratory test , vital sign , International Prostate Symptom Score , maximum urine flow rate , adverse event , concomitant medication , compliance . All subject previously participate 12-week double-blind placebo control trial ( NCT000224107 NCT000224120 )</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Males good general health least 50 year age , complete SI04009 SI04010 . Medical condition would confound efficacy evaluation . Medical condition would unsafe use alphablocker . The use concomitant drug would confound efficacy evaluation . The use concomitant drug would unsafe alphablocker .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>benign prostatic hyperplasia , alpha blocker</keyword>
</DOC>